Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 31 Aug 2016 |
| Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine | 25 Aug 2016 |
| Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma | 23 Aug 2016 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 18 Aug 2016 |
| Articles of Association for Genmab A/S | 18 Aug 2016 |